Following the publication of a paper titled 'Vitamin D replacement in pregnant women in rural North India: a pilot study' by Sahu et al. (Eur J Clin Nutr 63, 1157 -1159 , a Letter to the Editor was received from DE Roth (doi:10.1038/ejcn.2010.1). The Letter and a Response to the letter by the authors, led by the corresponding author V Bhatia (doi:10.1038/ejcn.2010.2), were published online in February 2010 and follow this note in this print issue. A matter related to corrections that were made to the initial Letter to the Editor by Roth at the proof stage was raised by the respondent, which implied that the corrections made at this late stage to the letter altered the very essence of the debate that followed the original publication of the pilot study. We have hence decided to set the record straight by providing this note at the time of the print publication of this correspondence in our journal.
In the last paragraph of the original letter submitted to the journal, Roth states, 'it remains unknown whether maternal vitamin D deficiency affects fetal well-being or development in humans, regardless of observed changes in 25(OH)D concentration'. The final letter by Roth corrected at the proof stage and subsequently published online, however, reads, 'it remains unclear how maternal vitamin D supplementation affects fetal well-being or development in humans, regardless of observed changes in 25(OH)D concentration'. The fact that Bhatia and colleagues have quoted the sentence from the original letter from Roth in the last paragraph of their response demonstrates that they were responding to the statement in the original letter, and not that in the corrected proof.
In fairness, it is likely that the original letter by Roth was meant to refer to the issue of maternal vitamin D supplementation rather than to maternal vitamin D deficiency, for the consequences of the latter are well recognized, as pointed out by the respondents. However, making these important changes at the proof stage undermined the fair attempt at rebuttal by the respondents, which is the reasoning behind this note. We hope we have set the record straight.
We encourage letters and correspondence debating scientific issues arising out of publications in our journal. Although we also entertain correspondence raising other issues such as ethical considerations or conflicts of interest, we will not publish such correspondence, but will follow up, investigate and deal with them internally. average 25-hydroxyvitamin D (25(OH)D) concentration rises to a peak within 2 weeks, then gradually declines towards the baseline concentration over a period of about 2 months (Armas et al., 2004; Ilahi et al., 2008) . The single dose of 60 000 IU D3 administered by Sahu et al. in the 5th month of gestation would not be expected to have a perceptible effect on 25(OH)D concentrations in most women at delivery, which was the only time at which the biochemical response was assessed. Even the larger doses administered later in pregnancy would have been predicted to have minor effects on the 25(OH)D concentration measured at delivery, despite almost certainly having caused important but undetected elevations in 25(OH)D concentration during the third trimester. Therefore, it is incorrect to conclude from Sahu et al.'s report that the reported supplement regimens had little or no effect on vitamin D status during pregnancy.
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The interpretation of the data is further complicated by the unspecified variation in the precise length of the interval between D3 dosing and 25(OH)D measurement among participants. The simple average 25(OH)D concentration at delivery reported by the authors is not a meaningful estimate of a time-dependent biochemical outcome. Sahu et al. (2009) did not report measures of maternal or fetal safety, which have not yet been firmly established for high-dose vitamin D supplementation during pregnancy. As with measures of biochemical efficacy, the timing of safety assessments is crucial. The risk of maternal hypercalcemia was low for the doses selected, but would be highest when the circulating concentrations of vitamin D metabolites collectively exceed the capacity of the vitamin D binding protein (Kimball and Vieth, 2008) , which would most likely occur within the first 2 weeks after dose administration. Sahu et al. (2009) only reported maternal serum calcium concentration at delivery, thus missing the relevant window of exposure. Moreover, as it is unknown whether fetal safety is exclusively related to maternal calcium homeostasis, it is incumbent upon antenatal vitamin D trial investigators to perform and report measures of fetal development (for example, birth anthropometry, neonatal examination for congenital anomalies), perinatal outcomes and, ideally, longer-term developmental follow-up.
The authors' notion that 'it was unethical to continue with a group not receiving any cholecalciferol ' Sahu et al., 2009 ) is not well founded, particularly given the design flaws noted above and the lack of health outcome measures in their study. Clinical equipoise exists, as it remains unclear how maternal vitamin D supplementation affects fetal well-being or development in humans, regardless of the observed changes in 25(OH)D concentrations. Therefore, rigorous placebo-controlled trials of antenatal vitamin D supplementation are an ethical research strategy that should be implemented to establish the role of vitamin D status in maternal-fetal health in South Asia.
